Preprint · Jan 2026

Peripheral Blood Biomarkers in Frailty Risk Prediction Models: A Scoping Review

By lu; LYYWWL

Frailty is one of the most significant geriatric syndromes in aging populations worldwide, associated with falls, disability, hospitalization, and mortality. Current frailty assessment tools rely primarily on clinical scales, which are time-consuming, subjective, and have limited capacity to detect subclinical biological dysregulation. Peripheral blood biomarkers represent a promising alternative, offering objective, quantifiable, and scalable indicators for frailty risk prediction. In recent years, an increasing number of studies have developed risk prediction models that incorporate blood-based biomarkers—such as inflammatory cytokines (e.g., IL-6, hs-CRP), metabolic markers (e.g., albumin, HbA1c), and endocrine factors (e.g., vitamin D, free testosterone)—using both traditional regression methods and machine learning algorithms. However, the evidence is fragmented: studies vary widely in their biomarker panels, frailty definitions, modeling techniques, and validation strategies. A 2025 mapping review of blood biomarker–frailty associations explicitly noted that a robust, blood biomarker-based prediction model for frailty is still lacking, and no existing review has systematically mapped the prediction models themselves. To address this gap, this project will conduct a scoping review to systematically map the existing evidence on risk prediction models that integrate peripheral blood biomarkers for frailty in adults aged 60 years and older. The review will follow the Arksey & O‘Malley (2005) five-stage methodological framework, with enhancements by Levac et al. (2010) and the JBI Manual for Evidence Synthesis (2020). Reporting will adhere to the PRISMA Extension for Scoping Reviews (PRISMA-ScR). We will search PubMed, Embase, Web of Science, Scopus, Cochrane Library, CNKI, Wanfang, and VIP for English and Chinese original studies published between January 2015 and June 2026. Two independent reviewers will perform study selection and data extraction. The methodological quality of included prediction models will be assessed using the PROBAST (Prediction model Risk Of Bias ASsessment Tool). Expected outcomes include: 1. A comprehensive evidence map of blood biomarker-based frailty risk prediction models, including study characteristics, biomarker categories, modeling approaches, and model performance metrics. 2. A frequency-based summary of the most commonly incorporated peripheral blood biomarkers, classified by biological pathway. 3. A critical appraisal of methodological strengths and limitations across included studies, with emphasis on external validation, calibration reporting, and risk of bias. 4. Identification of key research gaps and recommendations for future model development and validation. The findings will be disseminated as a peer-reviewed journal article. This review will provide a systematic landscape of a rapidly growing but fragmented field, and will serve as a foundational reference for researchers aiming to develop or validate blood biomarker-based frailty prediction tools. All study materials (search strategies, screening records, data extraction templates, PROBAST assessments) will be made available on this OSF project page to ensure transparency and reproducibility.

doi.org/10.17605/osf.io/wrkstOpen accessBiomarkers

AgingResearch.News